Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03389308 · ClinicalTrials.gov registry record · Phase 2
Long Term Open-label Study Evaluating Safety of Diacerein 1% Ointment Topical Formulation in Subjects With Epidermolysis Bullosa Simplex
A Phase 2 study, sponsored by Castle Creek Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 51
- Enrollment target
NCT03389308 is a Phase 2 study that has completed, run by Castle Creek Pharmaceuticals. The registered enrollment target is 51 participants.
The verdict
NCT03389308, a Phase 2 study, has completed, sponsored by Castle Creek Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 51 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the long term safety and tolerability of diacerein 1% ointment for 2 treatment cycles in subjects with EBS that previously participated in the CCP-020-301 or the CCP-020-101 studies.
Interventions
- DRUG diacerein 1% ointment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2017-12-01 |
| Est. Completion | 2020-04-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03389308
The ClinicalTrials.gov registry entry for NCT03389308 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Castle Creek Pharmaceuticals, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which diacerein 1% ointment is the first listed.
NCT03389308 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03389308 about?
NCT03389308 is a clinical study titled "Long Term Open-label Study Evaluating Safety of Diacerein 1% Ointment Topical Formulation in Subjects With Epidermolysis Bullosa Simplex". The primary objective of this study is to evaluate the long term safety and tolerability of diacerein 1% ointment for 2 treatment cycles in subjects with EBS that previously participated in the CCP-020-301 or the CCP-020-101 studies.
What is the current status of trial NCT03389308?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 51 participants. The study started on 2017-12-01. Estimated completion is 2020-04-17.
What interventions are being tested in trial NCT03389308?
The interventions under investigation include: diacerein 1% ointment (DRUG).
Who is sponsoring clinical trial NCT03389308?
This trial is sponsored by Castle Creek Pharmaceuticals, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.